People at Svastia Genetics

Svastia combines the power of conventional DNA/RNA sequencing, along with advanced immuno-sequencing of B- and T-cell repertoires to select the right therapy or clinical trial for cancer patients. Svastia’s genomic sequencing the immune repertoire enables us to identify neutralizing antibodies that can be developed as novel drugs for cancer and other diseases. Svastia offers a combinatorial genetic screening platform that utilizes multiple genomic sequencing technologies DIFFERENTIATION Combinatorial genetic screening: Most of the others do not offer a single platform that combines the use of DNA, RNA and immune-repertoire sequencing Novel antibody drugs: Novel neutralizing antibodies can be identified and patented for certain cancer types/subtypes that have unmet needs. We have chosen 7 indications in which we analyze responders and non-responders What are the main risks (R&D, manufacturing, financing, competitors...) and how do you address them? RISKS: - R&D requires funding and this needs to be generated through equity financing - Healthcare market in cancer diagnostics and screening is slow to enter and generate revenues - Competitors with advanced funding levels MITIGATIONS: - Cancer diagnostic reporting based on genetic screening can generate revenues and reduce equity financing needs for R&D - Fee-for-service pharma projects can bring in revenues while also helping us generate IP and expertise

Parthiban Vijayarangakannan

CEO